GlassScriptPhysician profile
William A Chafin
NPI 1225122716
$18,499.57
in general payments reported to CMS, 2019-2025
33 companies · $2,712 in 2025
The $2,712 reported for 2025 was more than what 75% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,785 · 2020: $764 · 2021: $1,899 · 2022: $2,647 · 2023: $3,076 · 2024: $4,616 · 2025: $2,712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,499 · Consulting Fee: $850 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,499.47 |
| Consulting Fee | $850.00 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,390.90 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $2,233.63 | 2019-2025 | Enbrel, Otezla, Krystexxa |
| Ucb, INC. | $2,152.10 | 2019-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $1,725.75 | 2019-2025 | |
| Pfizer INC. | $1,079.79 | 2019-2025 | |
| Janssen Biotech, INC. | $907.31 | 2019-2025 | Tremfya, Simponi Aria |
| Genzyme Corporation | $567.12 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $558.43 | 2019-2025 | Orencia |
| Astrazeneca Pharmaceuticals LP | $557.17 | 2021-2024 | Saphnelo |
| Glaxosmithkline, LLC. | $429.18 | 2019-2025 | Benlysta |
| Horizon Therapeutics Plc | $402.03 | 2019-2023 | Krystexxa |
| Lilly USA, LLC | $376.85 | 2019-2024 | Taltz |
| Aurinia Pharma U.S., INC. | $289.38 | 2021-2025 | Lupkynis |
| Organon LLC | $278.68 | 2022-2025 | Hadlima, Renflexis |
| Genentech USA, INC. | $263.62 | 2019-2025 | Actemra |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $181.46 | 2019 | |
| Radius Health, INC. | $179.66 | 2019-2025 | Tymlos |
| Sobi, INC | $154.06 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $140.65 | 2023-2025 | Strensiq |
| Octapharma USA, INC. | $127.29 | 2023-2025 | Octagam Immune Globulin (Human) |
| Fresenius Kabi USA, LLC | $79.26 | 2023-2025 | Tyenne, Idacio |
| Sandoz INC. | $67.63 | 2023-2025 | Hyrimoz |
| Sanofi-Aventis U.S. LLC | $54.99 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $42.12 | 2023-2024 | Truxima |
| Merck Sharp & Dohme LLC | $41.10 | 2019 | |
| Hikma Pharmaceuticals USA | $38.39 | 2019 | |
| Grifols USA, LLC | $37.04 | 2023 | Gamunex-C |
| Medexus Pharma, INC. | $35.91 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $24.77 | 2025 | |
| Mallinckrodt Hospital Products INC. | $23.73 | 2025 | Acthar |
| Ani Pharmaceuticals, INC. | $23.19 | 2024 | Purified Cortrophin Gel |
| Sebela Pharmaceuticals INC. | $19.31 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $17.07 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Chafin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.